Journal Report

THERAPEUTIC INNOVATION & REGULATORY SCIENCE

Download PDF
Journal Information
Journal Title
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
Publisher
SPRINGER HEIDELBERG
ISSN
2168-4790
E-ISSN
2168-4804
Database
Clarivate
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Post-marketing Safety Assessment in the ICH M14 Era: An International Comparison of Real-World Data Utilization Within Risk Management Plans in the European Union, Japan, and the Republic of Korea
Seung-Hun You, Hongsock Kim, Hyounggyoon Yoo et al.
2026-10-28
DOI: 10.1007/s43441-026-01068-x
Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots
Mónica Perea-Vélez, Marie Kirman, Anjana Patel et al.
2026-10-24
DOI: 10.1007/s43441-026-01051-6
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors
Ito Furukawa, Mamoru Narukawa
2026-10-23
DOI: 10.1007/s43441-026-01069-w
The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges
Fatma Nur Cicin
2026-10-23
DOI: 10.1007/s43441-026-01067-y
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan
Shingo Yamaguchi, Eiji Nakatani, Ryuta Asada
2026-10-23
DOI: 10.1007/s43441-026-01063-2
Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA)
Paul Marvin Quizon, Patriz Miga Lintag-Raymundo, Wan Lee Chow et al.
2026-10-22
DOI: 10.1007/s43441-026-01070-3
Analytical Advances and Evidence-Proportionate Biosimilar Development
Ryosuke Kuribayashi, Miya Kawasaki, Kanoko Goto
2026-10-21
DOI: 10.1007/s43441-026-01065-0
A Pragmatic Implementation Framework for Phase 2 Trials with Invasive Endpoints: Estimands, Missing Outcomes, and Decision-Ready Evidence
Dang Anh Tuan
2026-10-21
DOI: 10.1007/s43441-026-01066-z
The Inflation Reduction Act’s Modeled Impacts upon Late-Stage R&D
Harry P. Bowen, Gwen O’Loughlin, Claire Schleicher et al.
2026-10-20
DOI: 10.1007/s43441-026-01061-4
Comparison of Labeled Dosages Between Japan and the United States for Drugs Approved in Japan from 2020 to 2025
Takashi Funatogawa, Akihiro Yoshida
2026-10-20
DOI: 10.1007/s43441-026-01064-1
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 31, 2026 15:55